vanzacaftor + tezacaftor + deutivacaftor

vanzacaftor + tezacaftor + deutivacaftor is an oral, once-daily fixed-dose **small molecule** triple-combination CFTR modulator therapy developed by Vertex Pharmaceuticals for **cystic fibrosis**. It combines **vanzacaftor** and **tezacaftor**, which act as CFTR correctors to improve folding, trafficking, and cell-surface expression of defective cystic fibrosis transmembrane conductance regulator protein, with **deutivacaftor**, a CFTR potentiator that enhances channel gating activity at the cell surface. The regimen is intended for patients with cystic fibrosis who have at least one responsive **CFTR** variant or a variant resulting in production of CFTR protein, including patients with at least one **F508del** mutation. It is marketed as Alyftrek and was described in the provided context as FDA approved in December 2024 and approved in the European Union in June 2025.

Brand names

Alyftrek

Other names

vanzacaftor + tezacaftor + deutivacaftorvanzacaftor + tezacaftor + deutivacaftor fixed-dose combinationvanzacaftor-tezacaftor-deutivacaftor